APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cutaneous Leishmaniasis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cutaneous Leishmaniasis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025192 pages

Choose your research edition.

Industry ResearchCutaneous Leishmaniasis Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Cutaneous Leishmaniasis Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Cutaneous Leishmaniasis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cutaneous Leishmaniasis Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Cutaneous Leishmaniasis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Cutaneous Leishmaniasis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cutaneous Leishmaniasis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cutaneous Leishmaniasis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cutaneous Leishmaniasis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cutaneous Leishmaniasis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cutaneous Leishmaniasis Drugs include GSK, Albert David, Bristol-Myers Squibb, Gilead Sciences, Knight Therapeutics, Profounda, Pfizer, Novartis and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cutaneous Leishmaniasis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cutaneous Leishmaniasis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cutaneous Leishmaniasis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cutaneous Leishmaniasis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Cutaneous Leishmaniasis Drugs Segment by Company

GSK

Albert David

Bristol-Myers Squibb

Gilead Sciences

Knight Therapeutics

Profounda

Pfizer

Novartis

Sanofi

Xinhua Pharma

Cutaneous Leishmaniasis Drugs Segment by Type

Anti-Leishmanial/Antimicrobial Drugs

Antifungal Drugs

Pentavalent Antimonials

Cutaneous Leishmaniasis Drugs Segment by Application

Retail Pharmacy

Hospital

Others

Cutaneous Leishmaniasis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cutaneous Leishmaniasis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cutaneous Leishmaniasis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cutaneous Leishmaniasis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cutaneous Leishmaniasis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cutaneous Leishmaniasis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cutaneous Leishmaniasis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cutaneous Leishmaniasis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cutaneous Leishmaniasis Drugs Industry Trends Table 2. Cutaneous Leishmaniasis Drugs Industry Drivers Table 3. Cutaneous Leishmaniasis Drugs Industry Opportunities and Challenges Table 4. Cutaneous Leishmaniasis Drugs Industry Restraints Table 5. Global Cutaneous Leishmaniasis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cutaneous Leishmaniasis Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Manufacturers Table 9. Global Cutaneous Leishmaniasis Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cutaneous Leishmaniasis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cutaneous Leishmaniasis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cutaneous Leishmaniasis Drugs Manufacturers, Product Type & Application Table 13. Global Cutaneous Leishmaniasis Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cutaneous Leishmaniasis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Anti-Leishmanial/Antimicrobial Drugs Table 17. Major Manufacturers of Antifungal Drugs Table 18. Major Manufacturers of Pentavalent Antimonials Table 19. Global Cutaneous Leishmaniasis Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Cutaneous Leishmaniasis Drugs Sales by Type (2021-2026) & (K Units) Table 21. Global Cutaneous Leishmaniasis Drugs Sales by Type (2027-2032) & (K Units) Table 22. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type (2021-2026) Table 23. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type (2027-2032) Table 24. Global Cutaneous Leishmaniasis Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Cutaneous Leishmaniasis Drugs Revenue by Type (2021-2026) & (K Units) Table 26. Global Cutaneous Leishmaniasis Drugs Revenue by Type (2027-2032) & (K Units) Table 27. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Retail Pharmacy Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Others Table 32. Global Cutaneous Leishmaniasis Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Cutaneous Leishmaniasis Drugs Sales by Application (2021-2026) & (K Units) Table 34. Global Cutaneous Leishmaniasis Drugs Sales by Application (2027-2032) & (K Units) Table 35. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application (2021-2026) Table 36. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application (2027-2032) Table 37. Global Cutaneous Leishmaniasis Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Cutaneous Leishmaniasis Drugs Revenue by Application (2021-2026) & (K Units) Table 39. Global Cutaneous Leishmaniasis Drugs Revenue by Application (2027-2032) & (K Units) Table 40. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Cutaneous Leishmaniasis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Cutaneous Leishmaniasis Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Region (2021-2026) Table 45. Global Cutaneous Leishmaniasis Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Cutaneous Leishmaniasis Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Cutaneous Leishmaniasis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Cutaneous Leishmaniasis Drugs Sales by Country (2021-2026) & (K Units) Table 49. North America Cutaneous Leishmaniasis Drugs Sales by Country (2027-2032) & (K Units) Table 50. Europe Cutaneous Leishmaniasis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Cutaneous Leishmaniasis Drugs Sales by Country (2021-2026) & (K Units) Table 52. Europe Cutaneous Leishmaniasis Drugs Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Cutaneous Leishmaniasis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Cutaneous Leishmaniasis Drugs Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Cutaneous Leishmaniasis Drugs Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Cutaneous Leishmaniasis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Cutaneous Leishmaniasis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Cutaneous Leishmaniasis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Region (2027-2032) Table 64. GSK Company Information Table 65. GSK Business Overview Table 66. GSK Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. GSK Cutaneous Leishmaniasis Drugs Product Portfolio Table 68. GSK Recent Development Table 69. Albert David Company Information Table 70. Albert David Business Overview Table 71. Albert David Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Albert David Cutaneous Leishmaniasis Drugs Product Portfolio Table 73. Albert David Recent Development Table 74. Bristol-Myers Squibb Company Information Table 75. Bristol-Myers Squibb Business Overview Table 76. Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Product Portfolio Table 78. Bristol-Myers Squibb Recent Development Table 79. Gilead Sciences Company Information Table 80. Gilead Sciences Business Overview Table 81. Gilead Sciences Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Gilead Sciences Cutaneous Leishmaniasis Drugs Product Portfolio Table 83. Gilead Sciences Recent Development Table 84. Knight Therapeutics Company Information Table 85. Knight Therapeutics Business Overview Table 86. Knight Therapeutics Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Knight Therapeutics Cutaneous Leishmaniasis Drugs Product Portfolio Table 88. Knight Therapeutics Recent Development Table 89. Profounda Company Information Table 90. Profounda Business Overview Table 91. Profounda Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Profounda Cutaneous Leishmaniasis Drugs Product Portfolio Table 93. Profounda Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Pfizer Cutaneous Leishmaniasis Drugs Product Portfolio Table 98. Pfizer Recent Development Table 99. Novartis Company Information Table 100. Novartis Business Overview Table 101. Novartis Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Novartis Cutaneous Leishmaniasis Drugs Product Portfolio Table 103. Novartis Recent Development Table 104. Sanofi Company Information Table 105. Sanofi Business Overview Table 106. Sanofi Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Sanofi Cutaneous Leishmaniasis Drugs Product Portfolio Table 108. Sanofi Recent Development Table 109. Xinhua Pharma Company Information Table 110. Xinhua Pharma Business Overview Table 111. Xinhua Pharma Cutaneous Leishmaniasis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Xinhua Pharma Cutaneous Leishmaniasis Drugs Product Portfolio Table 113. Xinhua Pharma Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Cutaneous Leishmaniasis Drugs Distributors List Table 117. Cutaneous Leishmaniasis Drugs Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Cutaneous Leishmaniasis Drugs Product Image Figure 2. Global Cutaneous Leishmaniasis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cutaneous Leishmaniasis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Cutaneous Leishmaniasis Drugs Sales (2021-2032) & (K Units) Figure 5. Global Cutaneous Leishmaniasis Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cutaneous Leishmaniasis Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Anti-Leishmanial/Antimicrobial Drugs Image Figure 9. Antifungal Drugs Image Figure 10. Pentavalent Antimonials Image Figure 11. Global Cutaneous Leishmaniasis Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Cutaneous Leishmaniasis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Cutaneous Leishmaniasis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Cutaneous Leishmaniasis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Type (2021-2032) Figure 17. Retail Pharmacy Image Figure 18. Hospital Image Figure 19. Others Image Figure 20. Global Cutaneous Leishmaniasis Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Cutaneous Leishmaniasis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Cutaneous Leishmaniasis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Cutaneous Leishmaniasis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Cutaneous Leishmaniasis Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Cutaneous Leishmaniasis Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Cutaneous Leishmaniasis Drugs Sales Market Share by Country (2021-2032) Figure 40. China Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Cutaneous Leishmaniasis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Cutaneous Leishmaniasis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Cutaneous Leishmaniasis Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Cutaneous Leishmaniasis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Cutaneous Leishmaniasis Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Cutaneous Leishmaniasis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Cutaneous Leishmaniasis Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Cutaneous Leishmaniasis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Cutaneous Leishmaniasis Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Cutaneous Leishmaniasis Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-Leishmanial/Antimicrobial Drugs
  • Antifungal Drugs
  • Pentavalent Antimonials
Applications
  • Retail Pharmacy
  • Hospital
  • Others
Companies covered
  • GSK
  • Albert David
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Knight Therapeutics
  • Profounda
  • Pfizer
  • Novartis
  • Sanofi
  • Xinhua Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cutaneous Leishmaniasis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cutaneous Leishmaniasis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cutaneous Leishmaniasis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cutaneous Leishmaniasis Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cutaneous Leishmaniasis Drugs Market Dynamics
  1. 2.1 Cutaneous Leishmaniasis Drugs Industry Trends
  2. 2.2 Cutaneous Leishmaniasis Drugs Industry Drivers
  3. 2.3 Cutaneous Leishmaniasis Drugs Industry Opportunities and Challenges
  4. 2.4 Cutaneous Leishmaniasis Drugs Industry Restraints
3 Cutaneous Leishmaniasis Drugs Market by Manufacturers
  1. 3.1 Global Cutaneous Leishmaniasis Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cutaneous Leishmaniasis Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cutaneous Leishmaniasis Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cutaneous Leishmaniasis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cutaneous Leishmaniasis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cutaneous Leishmaniasis Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Cutaneous Leishmaniasis Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cutaneous Leishmaniasis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cutaneous Leishmaniasis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cutaneous Leishmaniasis Drugs Tier 1, Tier 2, and Tier 3
4 Cutaneous Leishmaniasis Drugs Market by Type
  1. 4.1 Cutaneous Leishmaniasis Drugs Type Introduction
  2. 4.1.1 Anti-Leishmanial/Antimicrobial Drugs
  3. 4.1.2 Antifungal Drugs
  4. 4.1.3 Pentavalent Antimonials
  5. 4.2 Global Cutaneous Leishmaniasis Drugs Sales by Type
  6. 4.2.1 Global Cutaneous Leishmaniasis Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Cutaneous Leishmaniasis Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Cutaneous Leishmaniasis Drugs Revenue by Type
  10. 4.3.1 Global Cutaneous Leishmaniasis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Cutaneous Leishmaniasis Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Type (2021-2032)
5 Cutaneous Leishmaniasis Drugs Market by Application
  1. 5.1 Cutaneous Leishmaniasis Drugs Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Cutaneous Leishmaniasis Drugs Sales by Application
  6. 5.2.1 Global Cutaneous Leishmaniasis Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cutaneous Leishmaniasis Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Cutaneous Leishmaniasis Drugs Revenue by Application
  10. 5.3.1 Global Cutaneous Leishmaniasis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cutaneous Leishmaniasis Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Application (2021-2032)
6 Global Cutaneous Leishmaniasis Drugs Sales by Region
  1. 6.1 Global Cutaneous Leishmaniasis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cutaneous Leishmaniasis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Cutaneous Leishmaniasis Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Cutaneous Leishmaniasis Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cutaneous Leishmaniasis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cutaneous Leishmaniasis Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cutaneous Leishmaniasis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cutaneous Leishmaniasis Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cutaneous Leishmaniasis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cutaneous Leishmaniasis Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cutaneous Leishmaniasis Drugs Revenue by Region
  1. 7.1 Global Cutaneous Leishmaniasis Drugs Revenue by Region
  2. 7.1.1 Global Cutaneous Leishmaniasis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cutaneous Leishmaniasis Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Cutaneous Leishmaniasis Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cutaneous Leishmaniasis Drugs Revenue (2021-2032)
  8. 7.2.2 North America Cutaneous Leishmaniasis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cutaneous Leishmaniasis Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Cutaneous Leishmaniasis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cutaneous Leishmaniasis Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cutaneous Leishmaniasis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Cutaneous Leishmaniasis Drugs Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Albert David
  8. 8.2.1 Albert David Company Information
  9. 8.2.2 Albert David Business Overview
  10. 8.2.3 Albert David Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Albert David Cutaneous Leishmaniasis Drugs Product Portfolio
  12. 8.2.5 Albert David Recent Developments
  13. 8.3 Bristol-Myers Squibb
  14. 8.3.1 Bristol-Myers Squibb Company Information
  15. 8.3.2 Bristol-Myers Squibb Business Overview
  16. 8.3.3 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Cutaneous Leishmaniasis Drugs Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 Knight Therapeutics
  26. 8.5.1 Knight Therapeutics Company Information
  27. 8.5.2 Knight Therapeutics Business Overview
  28. 8.5.3 Knight Therapeutics Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Knight Therapeutics Cutaneous Leishmaniasis Drugs Product Portfolio
  30. 8.5.5 Knight Therapeutics Recent Developments
  31. 8.6 Profounda
  32. 8.6.1 Profounda Company Information
  33. 8.6.2 Profounda Business Overview
  34. 8.6.3 Profounda Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Profounda Cutaneous Leishmaniasis Drugs Product Portfolio
  36. 8.6.5 Profounda Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Cutaneous Leishmaniasis Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Cutaneous Leishmaniasis Drugs Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Cutaneous Leishmaniasis Drugs Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
  55. 8.10 Xinhua Pharma
  56. 8.10.1 Xinhua Pharma Company Information
  57. 8.10.2 Xinhua Pharma Business Overview
  58. 8.10.3 Xinhua Pharma Cutaneous Leishmaniasis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Xinhua Pharma Cutaneous Leishmaniasis Drugs Product Portfolio
  60. 8.10.5 Xinhua Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cutaneous Leishmaniasis Drugs Value Chain Analysis
  2. 9.1.1 Cutaneous Leishmaniasis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cutaneous Leishmaniasis Drugs Production Mode & Process
  6. 9.2 Cutaneous Leishmaniasis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cutaneous Leishmaniasis Drugs Distributors
  9. 9.2.3 Cutaneous Leishmaniasis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst